AGIO vs. NVO

In the year-to-date period, AGIO achieves a -15.82% return, which is significantly higher than NVO's -31.39% return. Over the past 10 years, AGIO has underperformed NVO with an annualized return of -12.40%, while NVO has yielded a comparatively higher 9.70% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AGIO Sharpe Ratio is -0.07, which is higher than the NVO Sharpe Ratio of -1.25. The chart below compares the historical Sharpe Ratios of AGIO and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

AGIO has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 2.78%.

The maximum AGIO drawdown since its inception was -87.36%, which is greater than NVO's maximum drawdown of -70.96%. Use the drawdown chart below to compare losses from any high point for AGIO and NVO. For additional features, visit the drawdowns tool.

Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 18.66% compared to Novo Nordisk A/S (NVO) at 15.88%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.